*CLIMB BIO REPORTS FOURTH QUARTER AND YEAR-END 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
*CLIMB BIO INC - EXPECTS CASH RUNWAY THROUGH 2027
*CLIMB BIO INC: QTRLY LOSS PER SHARE $0.13
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 25-MAR-202520:05:08.237 GMT